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To describe the clinical features of individuals hospitalized for postpartum invasive group A Streptococcus (GAS) infection, a
retrospective, population-based study of hospitalized patients in the state of Florida was conducted. Cases of postpartum invasive
GAS infection (occurring within 42 days of delivery) were compared to women with other manifestations of invasive GAS
disease with respect to their age at the time of admission. Four cases of postpartum invasive GAS infection were detected in
this population, yielding a prevalence of 1.6% (4/257) of postpartum disease in this invasive GAS infection database. Patients
presented a median of 4 days (mean of 9 days) after delivery with signs and symptoms of infection. Three cases were complicated
by bacteremia and one patient had streptococcal toxic shock syndrome. Each patient received multiple antibiotics and survived.
No patients received intravenous immunoglobulin. For comparison, a secondary retrospective investigation of a large hospital
discharge dataset obtained from the Florida Agency for Health Care Administration was assessed for patients with puerperal GAS
infections. Thismethod yielded an additional three cases, whose clinical and demographic characteristics were summarized. These
data highlight that postpartum invasive GAS infection continues to complicate pregnancy, though the frequency has decreased
markedly over the past century.
Copyright © 2008 D. M. Aronoﬀ and Z. D. Mulla. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Puerperal sepsis causes at least 75000 maternal deaths
annually, mostly in developing countries, and the morbidity
ofpuerperalinfectionsaﬀectsanestimated5%–10%ofpreg-
nant women [1]. At one time, group A β-hemolytic Strepto-
coccus (GAS, S. pyogenes) was the major microbial cause of
postpartum infection [2]. Indeed, in the late 19th century,
Louis Pasteur is credited with discovering that puerperal
sepsis was predominantly caused by streptococci [2]. While
today other microbes such as group B streptococci, gono-
cocci, Chlamydia, herpes simplex, genital Mycoplasma,a n d
bacterial vaginosis are more often implicated in postpartum
fever, severe cases of puerperal fever are almost always caused
by GAS [1]. Worldwide, it is estimated that severe GAS
disease (including acute rheumatic fever and invasive infec-
tions) is responsible for over 500000 deaths annually [3].
It has been noted that the obstetric patient is especially
vulnerable to invasive GAS infection acquired via disrupted
mucosal or cutaneous barriers during delivery [4]. Post-
partum GAS infections in the modern era are a mixture
of illnesses of endogenous (patient) origin and acquired
(iatrogenic/nosocomial) infections [4]. Outbreaks of post-
partum GAS infection continue to be reported, and are often
related to the spread of GAS among postpartum patients by
healthcare works that are asymptomatic carriers [4].
The Centers for Disease Control and Prevention (CDC)
conduct population-based, active laboratory surveillance for
invasive GAS disease in the United States [5]. According to
the CDC, approximately 232 cases of postpartum invasive
GAS infection occurred in the United States in 1997, an
incidence of 0.06 cases per 1000 live births [4]. We previ-
ously published an extensive investigation of invasive GAS
infections that were reported to the Florida Department of2 Infectious Diseases in Obstetrics and Gynecology
Healthbetween1996and2000[6].Thedatabaseusedforour
original study included 257 hospitalized patients, providing
a relatively large sample size for exploring postpartum GAS
infection. Therefore, the objective of this study was to report
the detailed clinical and epidemiologic features of women
hospitalized for postpartum invasive GAS disease in Florida
during the four-year period of 1996–2000.
2. MATERIAL AND METHODS
2.1. Sourceofpatientsandinclusioncriteriafor
primaryretrospectivestudy
Previously unpublished demographic and clinical data on
postpartum invasive GAS disease from a study conducted
in Florida, the methods of which are described in detail
elsewhere, were accessed [6, 7]. The original study popula-
tion was comprised of 257 patients who were hospitalized
throughout the state of Florida between August 1996 and
August 2000 for invasive GAS disease and reported to
the Florida Department of Health (Tallahassee, Fla, USA).
Invasive GAS disease was deﬁned as isolation of group A
Streptococcus from a normally sterile site (e.g., blood, cere-
brospinal ﬂuid, joint ﬂuid, pleural ﬂuid, or pericardial ﬂuid)
and a clinically compatible presentation. The deﬁnition of a
clinically compatible presentation was one of several entities,
including pneumonia, bacteremia in association with cuta-
neous infection (e.g., cellulitis, erysipelas, or infection of a
surgical or nonsurgical wound), deep soft-tissue infection
(e.g., myositis), meningitis, peritonitis, osteomyelitis, septic
arthritis, postpartum sepsis (i.e., puerperal fever), neonatal
sepsis, and nonfocal bacteremia. The original study also
included cases of necrotizing fasciitis if GAS was isolated
from a nonsterile site. Streptococcal toxic shock syndrome
(STSS) was deﬁned as reported by the CDC Working Group
on Severe Streptococcal Infections [8].
For each case of invasive GAS disease that was reported
by a county health department to the Florida Department of
Health,athree-pagecasereportformwascompletedafterthe
review of the patient’s medical record [7]. This chart review
was usually performed by an epidemiology staﬀ member at
the reporting county health department. The surveillance
case report form contained a section which required the
chart reviewer to check oﬀ the diseases caused by group
A Streptococcus including “endometritis/postpartum sepsis.”
[9]. Another section captured information on underlying
illnesses and risk factors including “pregnancy/peripartum”
via a check box [9]. Cases were included in our current
analysis if endometritis/postpartum sepsis was noted on
the surveillance form and/or “pregnancy/peripartum” was
checked oﬀ in the risk factor portion of the form and
the infection occurred within 42 days of delivery. Although
puerperal infection is most commonly encountered within
the ﬁrst 2 weeks after delivery, the deﬁnition extends to 42
days postpartum [1]. A cutoﬀ of 42 days was employed to
include the conventional duration of the puerperium, that
period between the completion of delivery and the return
of the reproductive tract to its nonpregnant condition. In
addition, postpartum invasive GAS infections have been
reported to occur up to 6 weeks after delivery [10]. The risk
factor section included various conditions including obesity,
diabetes, chronic lung disease, chronic heart disease, alco-
hol abuse, and noncutaneous malignancies. Antimicrobial
therapy that was received during the hospitalization was also
noted on the surveillance form.
2.2. Secondarycomparativeanalysis
The health department surveillance dataset did not contain
the patients’ lengths of stay. Length of stay is a recognized
measureofdiseaseseveritywhenassessingpregnancy-related
morbidity [11]. Lengths of stay were available in a large
Florida hospital discharge dataset that was obtained from
the Florida Agency for Health Care Administration. As an
alternative method and comparator to the above investiga-
tion, we retrospectively queried this Florida hospital dis-
charge dataset. This public-use database includes discharge
summaries from all nonfederal Florida hospitals except state
tuberculosis and state mental health hospitals [12]. After
data are entered into this system, they are subjected to
formatting and logic checks. This dataset contained clinical
and demographic information for 2, 343, and 330 patients
who were hospitalized in a reporting facility and discharged
in calendar year 2001. The principal discharge diagnosis and
up to nine secondary discharge diagnoses were coded using
the International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation (ICD-9-CM). Procedures performed
during the hospital stay were also coded using ICD-9-CM.
The discharge database was searched for women carrying
the diagnosis of postpartum invasive GAS disease who were
residents of Florida. While there is no ICD-9-CM code
for “invasive group A streptococcal infection,” postpartum,
or otherwise, these cases can be found by searching for
women whose electronic discharge record contained both
an ICD-9-CM code for “major puerperal infection” (670.00,
670.02, and 670.04) and the code for “group A strepto-
coccal infection” (041.01). Three such cases were found in
the discharge dataset, and their clinical and demographic
characteristics were summarized. Finally, the 2001 incidence
rate of postpartum invasive GAS disease was calculated by
dividing the 3 cases by the number of resident live births in
Florida in 2001 [13].
2.3. Statisticalanalysis
SAS for Windows 9.1.3 (Cary, NC, USA) was used to manage
and analyze the data. Cases of postpartum invasive GAS
infection were compared to women with other manifesta-
tions of invasive GAS disease with respect to their age at
the time of admission. Median ages are reported along with
a two-sided P-value from a two-sample Wilcoxon test. The
small number of postpartum cases (n = 4) prevented a
comprehensive statistical analysis. Analyses of all databases
wereapprovedbytheInstitutional ReviewBoardoftheTexas
TechUniversityHealthSciencesCenterSchoolofMedicineat
El Paso.D. M. Aronoﬀ and Z. D. Mulla 3
Table 1: Clinical, laboratory, and epidemiologic characteristics of postpartum invasive group A streptococcal infections.
Case Year of
admission
Age (years)
Symptom
onset (days
postpartum)
Race and
Hispanic
ethnicity
Clinical
presentation
Potential risk fac-
torsotherthanpe-
ripartum period
GAS∗ isolate
site(s) Outcome
1 1996 36 22 White non-
Hispanic Peritonitis Injecting drug user Peritoneal
ﬂuid Survived
2 1997 26 1 Black non-
Hispanic
Pneumonia
(None) Genitals,
blood Survived Secondary
bacteremia
3 1998 29 4 White Hispanic
Endometritis/
postpartum
sepsis
Surgical wound
Blood Survived Secondary
bacteremia
Use of NSAIDs∗∗
in 7 days prior to
onsetofGASillness
STSS#
4 1999 25 NA White non-
Hispanic
Endometritis/
postpartum
sepsis (None) Blood, vagina Survived
Secondary
bacteremia
∗Group A Streptococcus.
†At the time of admission.
‡NA: not available.
#STSS: streptococcal toxic shock syndrome.
∗∗NSAIDs: nonsteroidal anti-inﬂammatory drugs.
3. RESULTS
Clinical, laboratory, and epidemiologic features of the four
cases identiﬁed by the Florida Department of Health are
shown in Table 1. According to the public health surveillance
form, none of the cases had pharyngitis, necrotizing fasciitis,
or toxic shock syndrome caused by group A Streptococcus.
The median age of the postpartum cases was 27.5 years while
the median age of the 116 women hospitalized with other
manifestations of invasive GAS disease was 54 years (two-
sided Wilcoxon P = .04). GAS bacteremia was noted in cases
2through4(Table 1).Thehospitalmortalityratewas0%.Of
the three cases (cases 2 through 4) whose surveillance forms
had known values for the receipt of IVIG, none had received
IVIG during the hospital stay (data not shown). Patients
presented a median of 4 days (mean of 9 days) after delivery
with signs and symptoms of infection. One patient met the
case deﬁnition of STSS (Case 3 below).
Case1wasa36-yearoldinjectingdruguser(Table 1)and
had been a smoker in the 6 months preceding the current
admission (data not shown). She developed peritonitis
approximately 3 weeks postpartum with GAS. The interval
between the onset of her symptoms and hospital admission
was one day. The patient was admitted to the hospital from
her doctor’s oﬃce with the suspected (admitting) diagnosis
of “rule out appendicitis.” She did not undergo surgery but
was treated with parenteral cefazolin and metronidazole.
Her highest temperature with 48 hours of admission was
103.0
◦ F.
Case 2 was delivered her baby one day preceding the
onset of GAS infection. Her surveillance form indicated the
presence of pneumonia and GAS bacteremia secondary to
the pulmonary focus of infection. She had cough, fever,
vomiting, abdominal pain, and diarrhea at the time of (or
within 48 hours of) admission. Her nadir blood pressure was
98/48mmHg.Thepatientreceiveddoxycycline,vancomycin,
gentamicin, metronidazole, and ampicillin/sulbactam.
Case 3 was admitted on the day that she developed
symptoms of invasive GAS infection. She was a Hispanic
woman admitted with postpartum endometritis and sepsis.
She had undergone a bilateral tubal ligation at the time
of her delivery, three days prior to her admission. Her
case was complicated by STSS, as evidenced by hypotension
requiring vasopressive agents (nadir systolic blood pressure
on admission was 76mmHg); hypoalbuminemia; a macular
erythematous rash involving her abdomen and thighs; and
elevatedaspartateaminotransferaseandalanineaminotrans-
ferase values on admission (609U/L and 80U/L, resp.) [14].
She was treated in an intensive care unit with gentamicin,
clindamycin, penicillin, and cefepime and survived.
Case 4 was admitted with a diagnosis of postpartum
fever two days after her symptoms began, though the onset
of her infection in relation to her delivery date could not
be determined. She was diagnosed with “bacteremia” and
“endometritis/postpartum sepsis” on the surveillance form
and GAS was isolated both from vaginal and blood cultures.
Her highest temperature within 48 hours of admission was
101
◦ F. She was treated with tobramycin, clindamycin, and
ampicillin. Shewasdischarged onhospital dayﬁvewitha10-
day course of oral amoxicillin-clavulinic acid.
The demographic and clinical features of the three
women hospitalized for a postpartum invasive GAS infection4 Infectious Diseases in Obstetrics and Gynecology
Table 2:Clinicalanddemographiccharacteristicsofwomendischargedin2001inFloridawithICD-9-CMcodes∗ indicatingtheoccurrence
of a postpartum invasive group A streptococcal infection.
Case Age
(years)
Race and
Hispanic
ethnicity
Type of
admission
Principal
diagnosis
Selected secondary
diagnoses
Principal
procedure
Length
of stay
(days)
Outcome
A 36 Black Non-
Hispanic Emergent Streptococcal
septicemia
Major puerperal infection Acute Venous cathe-
terization not
elsewhere clas-
siﬁed (exclud-
ing that for ca-
rdiac catheter-
ization or renal
dialysis)
9 Survived
posthemorrhagic anemia Pneu-
monia, organism unspeciﬁed
Group A streptococcal infection
Pain in cervical spine or neck
Joint pain (pelvic region and
thigh)
B 25 White Non-
Hispanic Emergent
Major
puerperal
infection
Streptococcal septicemia
Aspiration cur-
ettage of uterus 3 Survived
Retained portions of plac-
enta or membranes, with-
out hemorrhage Unspec-
iﬁedinﬂammatorydisease
of uterus—except cervix
(e.g., endometritis)Group
A streptococcal infection
C 19 White Non-
Hispanic Emergent
Major
puerperal
infection
Unspeciﬁed inﬂammatory
disease of uterus—except
cervix (e.g., endometritis) (None listed) 3 Survived
Group A streptococcal inf-
ection
∗ICD-9-CM: International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation.
(who were identiﬁed through analysis of the Florida Agency
for Health Care Administration discharge database) are
shown in Table 2. Cases A and B appeared to have GAS
bacteremia and sepsis, while cases B and C appeared to
have GAS endometritis or a similar inﬂammatory disease
of the uterus excluding the cervix (ICD-9-CM code 615.9).
This code is used for the following diseases: endometri-
tis, endomyometritis, metritis, myometritis, perimetritis,
pyometra, or uterine abscess. All three cases survived and
were discharged to their homes. The median length of stay
was 3 days. Dividing the frequency of three cases by 205800
live births yielded an annual incidence of 1.5 per 100000 live
births.
4. CONCLUSIONS
The objective of this analysis was to describe the clinical,
laboratory, and epidemiologic features of women hospital-
ized for postpartum invasive GAS disease, an uncommon
phenomenon. Using data from an active surveillance pro-
gram that operated in 9 regions of the United States, the
CDC calculated that 2.2% of all cases of invasive GAS disease
are postpartum infections [4]. We report a similar, though
somewhat lower prevalence: 1.6% (4/257) of the patients in
our invasive GAS infections database were women who had
postpartum disease.
Wahl et al. recently reported on 475 culture-conﬁrmed
cases of invasive GAS disease that were identiﬁed using a
voluntary laboratory surveillance system in Germany [15].
Nine of these infections (1.9%) were related to pregnancy.
Five of the cases delivered naturally while the remaining four
women underwent a cesarean section. A limitation of the
current study is that the mode of delivery was not recorded
on the case report forms.
These four cases emphasize that invasive GAS infections
occurring during the puerperium are not always limited
to the reproductive tract. One mother in our study (case
1) was an injection drug user with peritonitis occurring
approximately 3 weeks postpartum. Our research methods
precluded an accurate determination of the timing of
injection drug usage with the onset of peritonitis. How-
ever, intravenous drug use is a well-described risk factor
for invasive GAS infection and GAS peritonitis has been
reported in this population [16]. This case highlights the
importance for clinicians to consider GAS infections in
febrile or septic postpartum patients with known risk factors
for this disease, such as diabetes, alcohol dependence, or
injection drug usage. Another patient in our report (case 2)
suﬀered from pneumonia. Though rare in the postpartum
period, invasive GAS lower respiratory tract infections have
been reported [4]. We cannot determine the pathogenesis
of the pneumonia in our second case, which might have
occurredasacomplicationofhematogenousspreadfromthe
reproductive tract, autoinoculation of the respiratory tract,
or acquisition from another person.
One of the patients in our case series (case 3) had
taken one or more nonsteroidal anti-inﬂammatory drugs
(NSAIDs) during the seven days prior to the onset of GAS
disease. It has been suggested that the use of NSAIDs might
increase the risk of developing GAS necrotizing fasciitis orD. M. Aronoﬀ and Z. D. Mulla 5
could facilitate the progression of invasive GAS disease to
shockandmultiorganfailure[17–19].However,determining
a causal association between NSAID use and infectious
diseases has been diﬃcult, particularly with retrospective
studies [20, 21].
Our health department dataset (Table 1) spanning four
years (August 1996–August 2000) captured one case of
postpartum invasive GAS disease per year. To complement
these data, we searched a Florida hospital database for
women discharged throughout the state in 2001 whose
records contained ICD-9-CM codes indicating the presence
of postpartum invasive GAS disease. This is a logical source
of supplemental epidemiologic information given the fact
that a national study reported that 99% of women with
postpartum invasive GAS disease are hospitalized for their
illness [4]. The results from the health department database
and the discharge database complement one another and
are consistent with the epidemiology of postpartum invasive
GAS disease. Both databases revealed that the majority of
these patients do not have chronic comorbidities. Further-
more, all seven patients survived (Tables 1 and 2). According
toCDCsurveillancedata,thecase-fatalityrateofpostpartum
invasive GAS disease is lower than the case-fatality rate of
other invasive GAS infections in females of reproductive age
(3.5% versus 9.4%) [4].
Obstetricians should be aware of the clinical features
of GAS endometritis and/or disseminated infection. A
review of 47 cases of intrapartum or postpartum GAS
infection collected relevant clinical aspects of this disease
[10]. The majority of patients (83%) presented within 7
days of delivery, though a minority, presented almost 8
weeks postpartum. Fever, usually of sudden onset at the
time of presentation (or shortly thereafter), was nearly
uniform. For 65% of patients, fever was the sole presenting
symptom, while for others abdominal pain and/or heavy
vaginal bleeding were signiﬁcant complaints. A minority of
women (three of the 47) developed septic shock [10]. It
has been noted that women with postpartum GAS sepsis
generally present within the ﬁrst 24 hours after delivery with
fever, hypotension, tachycardia, leukocytosis, hemolysis, and
disseminated intravascular coagulation [22]. Such women
can present without evidence for pelvic infection [23].
The medical management of invasive GAS infections
is an evolving practice [17]. The CDC recommend high-
dose parenteral penicillin and clindamycin for toxic shock
syndrome or necrotizing fasciitis [24], a recommendation
echoed by the Infectious Diseases Society of America [25].
The CDC also recommends for patients with severe illness,
supportivecareinanintensivecareunitmightbeneededand
early and aggressive surgery is often needed for necrotizing
fasciitis cases to remove damaged tissue and stop disease
spread [24].
The patients in our study were more often than not
treated with multiple antibiotics. Two postpartum patients
received clindamycin, which has been associated with a sur-
vival advantage over β-lactam antibiotics in some studies of
invasive GAS [6, 26]. The mechanisms conferring a potential
treatment advantage for clindamycin are complex (reviewed
extensively in [14]). Clindamycin suppresses the production
of GAS virulence proteins, enhances the phagocytosis of
GAS by neutrophils, modiﬁes host inﬂammatory responses,
and is immune to the inoculum (“Eagle”) eﬀect wherein
GAS grown to high density or stationary phase exhibit
decreased sensitivity to penicillins [17]. Clindamycin use has
been advocated in the setting of STSS [27] and it is note
worthy in this regard that case 3 in this report, who suﬀered
from STSS, received clindamycin in combination with other
antimicrobials and survived. This case also underscores the
acute and fulminate nature that invasive GAS infections can
assume.
The use of newer anti-Gram positive antibiotics such as
dalbavancin, daptomycin, linezolid, and tigecycline in the
setting of GAS infections remains to be deﬁned [28]. If
necrotizing fasciitis is suspected then rapid consultations
with infectious disease clinicians and surgeons are impera-
tive. The use of IVIG has been advocated for invasive GAS
infections complicated by STSS (reviewed in [14]). None
of our 4 postpartum patients received IVIG and this might
reﬂect the low prevalence of STSS on clinical presentation.
Postpartum GAS infections can occur as a result of
an outbreak on a maternity ward [29]. We did not have
evidence that these four cases were related to an outbreak
of invasive GAS infections, although our study was not
designed to examine the interrelationships of cases in terms
of chronology and location. The four cases reported here
each occurred in a diﬀerent calendar year, suggesting they
were not part of one outbreak. Cases 1 and 2 resided in
separate counties that do not border one another. Cases 3
and 4 were residents of the same county at the time of their
illness; however, they were admitted almost 22 months apart
indicating that a cluster in space and time was not present.
Although this study was limited by its retrospective
nature, it conﬁrms the uncommon occurrence of post-
partum GAS infections in the modern era of antisepsis
and antimicrobials. It also underscores the importance of
recognizing GAS infection in the postpartum period and
instituting antimicrobial therapy early in the course of
infection to reduce the risk of an adverse outcome.
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